Last day of trading with the warrants of series TO 3 in Dicot
Today, June 13, 2022, is the last day of trading with the warrants of series TO 3. The subscription period for the warrants of series TO 3 will continue up until June 15, 2022.
Terms for the warrants of series TO 3 in short:
One (1) warrant of series TO 3 entitles the owner to subscribe for one (1) new share in the Company.
Subscription price: 0,29 SEK per new issued share
Volume: 38068461 warrants of series TO 3. If fully exercised, 38068461 new shares are issued, and the Company will receive at most approximately 11 MSEK before transaction costs
Subscription period: June 1, 2022 - June 15, 2022
Trading with warrants of series TO 3: Warrants of series TO 3 can be traded at Spotlight Stock Market under the ticker ``DICOT TO 3`` with ISIN-code SE0016844450. Last day of trading with warrants of series TO 3 is June 13, 2022.
Note that the warrants that are not used to subscribe for new shares, or are sold in the market before June 13, 2022, or are used for subscription at latest June 15, 2022, will expire and thus lose their value. To ensure that the warrant owner's warrants of series TO 3 don't expire without value the owner has to actively subscribe for shares or sell their warrants in the market.
Complete terms for the warrants of series TO 3 was included in the prospectus regarding the rights issue of units released on September 8, 2021. An independent document with complete terms for the warrants of series TO 3 as well as the prospectus is available at the above-mentioned web address.
How to use the warrants:
Trustee registered warrants (Custody account)
Subscription and payment with the use of warrants of series TO 3 shall be made in accordance with instructions from each trustee. If you have further questions regarding subscription and payment please contact your trustee for additional information in good time before June 15, 2022, as different trustees may have different processing times.
Directly registered warrants (Securities account)
Directly registered holders (holdings on a VP account) of warrants of series TO 3 must notify redemption of warrants by filling in and sending a notification form for the exercise of warrants, so that it is received by the issuing institution Hagberg & Aneborn Fondkommission AB no later than 15.00 on 15 June 2022.
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares (IS) awaiting registration at the Swedish Companies Registration Office.
Stockholm Corporate Finance AB is the financial adviser and Advokatfirman Lindahl KB is legal adviser regarding the warrants of series TO 3. Hagberg & Aneborn Fondkommission AB acts as issuing agent regarding the warrants of series TO 3.
Uppsala, June 13, 2022
For questions regarding the warrants, please contact:
Hagberg & Aneborn Fondkommission AB
Phone: + 46 (0) 840 89 33 50
Email: [email protected]
For additional questions regarding the warrants, please contact:
Elin Trampe, CEO
Phone: +46 (0) 739 80 14 08
Email: [email protected]
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se
Uppsala, 15 november 2022. Dicots senaste studie av verkningsmekanismen hos LIB-01, dvs hur läkemedlet fungerar i kroppen för att nå önskad effekt, visar att den skiljer sig från dagens potensläkemedel. Detta innebär att LIB-01 kan antas representera en ny generation av potensläkemedel.
Uppsala, November 15, 2022. Dicot's latest study of the mechanism of action of LIB-01, i.e., how the drug affects the body to achieve the desired effect, shows that it differentiates from today's potency drugs. This means that LIB-01 can be assumed to represent a new generation of potency drugs.
Uppsala, 14 november 2022. Dicot meddelar idag att det första formella myndighetsmötet för LIB-01 inför en ansökan om start av kliniska studier har genomförts. Detta var det första av två planerade vetenskapliga rådgivningsmöten med Läkemedelsverket, i syfte att förankra det underlag som ska ingå i en klinisk prövningsansökan.
Uppsala, November 14, 2022. Dicot announces today that the first regulatory meeting for LIB-01 prior to an application to start clinical trials has been conducted. This was the first of two planned scientific advisory meetings with the Swedish Medical Products Agency, with the purpose of anchoring the scientific background documentation for a clinical trial application.
Pressmeddelande: Uppsala, 3 november 2022. Enligt det beslut om valberedningen som fattades vid årsstämman i Dicot AB den 24 maj 2022 ska valberedningen inför årsstämman den 23 maj 2023 bestå av tre ledamöter representerande de tre största aktieägarna per den sista september 2022.
Press release: Uppsala, November 3, 2022. According to decision at the Annual General Meeting of Dicot AB on May 24, 2022, the Nomination committee for the Annual General Meeting on May 23, 2023, shall consist of three members representing the three largest shareholders as of the end of September 2022.
Pressmeddelande: Uppsala, 1 november 2022. Rättelsen avser att informera om att tidigare pressmeddelande gällande Dicot ABs (publ) delårsrapport för januari - september 2022 ej skulle ha varit markerad med MAR-etikett.
Press release: Uppsala, November 1, 2022. The correction is to inform that the previous press release regarding Dicot AB's (publ) interim report for January - September 2022 should not have been marked with the MAR label.
Pressmeddelande: Uppsala, 1 november 2022. Dicot ABs (publ) delårsrapport för januari - september 2022 finns nu tillgänglig på bolagets hemsida www.dicot.se.
Press release: Uppsala, November 1, 2022. A summary of the Interim report January - September 2022, for Dicot AB (publ) is now available on the company website www.dicot.se.
Publicering av Dicots rapport för tredje kvartalet kommer tidigareläggas till den 1 november 2022. Tidigare meddelat datum för publicering var den 15 november 2022
Publication of Dicot's report for the third quarter will be brought forward to November 1, 2022. Previously announced date for publication was November 15, 2022.
Uppsala, 25 oktober 2022. Dicot flyttar delar av tillverkningen av sin läkemedelssubstans för att sänka kostnader och minska transporter. Det är extraktionsprocessen som flyttas till Sydafrika där startmaterialet redan hanteras och där bolaget har etablerade samarbetspartners.
Uppsala, October 25, 2022. Dicot is moving parts of the manufacturing of its drug substance to lower costs and reduce transportations. It is the extraction process that is being moved to South Africa where the starting material is already handled and where the company has established collaboration partners.
Nyhet: Uppsala, 17 oktober 2022. Dicot AB meddelar idag att bolaget har skickat in en ny patentansökan till Patent- och registreringsverket. Detta följer den IP-plan som tidigare kommunicerats av bolaget. Nya patent ger 20 års marknadsexklusivitet från det att en ansökan skickas in.
News: Uppsala, October 17, 2022. Dicot AB announces today that the company has submitted a new patent application to the Patent and Registration Office. This is according to the IP plan previously communicated by the company. New patents provide 20 years of market exclusivity from the time an application is submitted.
Dicot rapporterar att de prekliniska toxikologistudierna som nu genomförs, hittills visar att läkemedelskandidaten LIB-01 har en god säkerhetsprofil.
Dicot reports that the preclinical toxicology studies that are now being conducted, so far show that the drug candidate LIB-01 has a good safety profile.
Uppsala, 7 september 2022. EU-kommissionen har utifrån tusentals små och medelstora europeiska företag valt ut Dicot som ett av bolagen att bjuda in till tävlingen Innovation Radar Prize 2022.
Uppsala, September 7, 2022. The European Commission has selected Dicot from thousands of small and medium-sized European companies as one of the companies to participate in the Innovation Radar Prize 2022.